IRIS
SALADINI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.669
EU - Europa 5.791
AS - Asia 2.719
SA - Sud America 523
Continente sconosciuto - Info sul continente non disponibili 264
AF - Africa 169
OC - Oceania 5
Totale 16.140
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.551
RU - Federazione Russa 1.294
GB - Regno Unito 1.192
IT - Italia 1.062
SG - Singapore 841
CN - Cina 767
IE - Irlanda 691
BR - Brasile 434
SE - Svezia 389
VN - Vietnam 331
DE - Germania 284
FR - Francia 260
HK - Hong Kong 255
UA - Ucraina 219
IN - India 123
FI - Finlandia 120
KR - Corea 99
ES - Italia 95
ZA - Sudafrica 94
BD - Bangladesh 63
CA - Canada 60
NL - Olanda 41
BE - Belgio 37
TR - Turchia 34
AR - Argentina 33
JP - Giappone 33
MX - Messico 32
PL - Polonia 28
IQ - Iraq 24
NG - Nigeria 24
PK - Pakistan 19
UZ - Uzbekistan 18
ID - Indonesia 14
EC - Ecuador 13
LT - Lituania 13
AT - Austria 12
CZ - Repubblica Ceca 12
IR - Iran 12
VE - Venezuela 12
KE - Kenya 11
AE - Emirati Arabi Uniti 10
CO - Colombia 10
KZ - Kazakistan 10
EG - Egitto 9
GR - Grecia 9
MA - Marocco 8
PY - Paraguay 8
SA - Arabia Saudita 8
JM - Giamaica 7
BO - Bolivia 6
EE - Estonia 6
ET - Etiopia 6
SK - Slovacchia (Repubblica Slovacca) 6
MY - Malesia 5
NP - Nepal 5
PT - Portogallo 5
AL - Albania 4
BH - Bahrain 4
CL - Cile 4
DO - Repubblica Dominicana 4
HN - Honduras 4
IL - Israele 4
JO - Giordania 4
LV - Lettonia 4
OM - Oman 4
PA - Panama 4
PH - Filippine 4
TN - Tunisia 4
AU - Australia 3
CR - Costa Rica 3
DZ - Algeria 3
LB - Libano 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
TH - Thailandia 3
AO - Angola 2
AZ - Azerbaigian 2
BW - Botswana 2
CI - Costa d'Avorio 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
PE - Perù 2
SN - Senegal 2
TM - Turkmenistan 2
AM - Armenia 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
EU - Europa 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
KH - Cambogia 1
MN - Mongolia 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NO - Norvegia 1
Totale 15.869
Salva come PNG Salva come JPEG
Città #
Southend 1.017
Dallas 861
Dublin 687
Fairfield 627
Ashburn 480
Singapore 461
Chandler 391
Moscow 357
Santa Clara 336
San Jose 322
Woodbridge 270
Beijing 245
Hong Kong 245
Siena 236
Seattle 230
Cambridge 224
Milan 218
Ann Arbor 213
Houston 210
Wilmington 201
Jacksonville 181
Council Bluffs 142
New York 119
Munich 117
Princeton 111
Rome 108
Los Angeles 106
Ho Chi Minh City 102
Hefei 99
Seoul 96
Johannesburg 89
Hanoi 69
Lauterbourg 68
Málaga 66
The Dalles 63
Helsinki 59
Nanjing 48
Boardman 45
San Mateo 44
São Paulo 44
Columbus 43
Buffalo 37
Shanghai 37
Bengaluru 36
Dong Ket 33
Brussels 31
London 30
Orem 30
San Diego 30
Dearborn 27
Montreal 27
Tokyo 27
Hangzhou 25
Abuja 23
Portsmouth 22
Chennai 21
Frankfurt am Main 21
Redondo Beach 21
Warsaw 21
Turku 20
Menlo Park 19
Nanchang 19
Atlanta 18
North Bergen 18
Phoenix 18
Manchester 17
Tashkent 17
Denver 16
Mexico City 16
Naples 16
Nuremberg 16
Toronto 16
Figino 15
Redwood City 14
San Francisco 14
Stockholm 14
Amsterdam 13
Chicago 13
Fremont 13
Mumbai 13
Shenyang 13
Düsseldorf 12
Izmir 12
Belo Horizonte 11
Boston 11
Brooklyn 11
Dhaka 11
Florence 11
Hebei 11
Lappeenranta 11
Baghdad 10
Brasília 10
Da Nang 10
Lancaster 10
Norwalk 10
Tianjin 10
Turin 10
Changsha 9
Rio de Janeiro 9
Astana 8
Totale 10.694
Salva come PNG Salva come JPEG
Nome #
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 335
Human DDX3 protein is a valuable target to develop broad spectrum antiviral agents 319
A novel methodology for large-scale phylogeny partition 309
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 308
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 304
(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity 303
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 303
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 301
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 299
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: A cohort study 290
Changing patterns in HIV-1 non-B clade prevalence and diversity in Italy over three decades 283
Synthesis and Antiviral Activity of Novel 1,3,4-Thiadiazole Inhibitors of DDX3X 267
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 263
Stability of unfrozen whole blood DNA for remote genotypic analysis of HIV-1 coreceptor tropism 262
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 262
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 260
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 257
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 257
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 254
Detection of residual human immunodeficiency virus type 1 reverse transcriptase K103N minority species in plasma RNA and peripheral blood mononuclear cell DNA following discontinuation of non-nucleoside therapy 252
Low-cost simultaneous detection of CCR5-delta32 and HLA-B*5701 alleles in human immunodeficiency virus type 1 infected patients by selective multiplex endpoint PCR 250
Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple 249
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients 248
Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy 243
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 242
Near Full-Length Sequence Analysis of HIV Type 1 BF Recombinants from Italy 240
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 240
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors 239
Identification of a Possible Ancestor of the Subtype A1 HIV Type 1 Variant Circulating in the Former Soviet Union 238
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 235
Discordances with HIV-1 RNA quantitative determinations by three commercial assays in Pointe Noire, Republic of Congo 232
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 232
Exploring the implication of DDX3X in DENV infection: discovery of the first-in-class DDX3X fluorescent inhibitor 231
Identification of novel 2-benzoxazolinone derivatives with specific inhibitory activity against the HIV-1 nucleocapsid protein 225
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors 219
Distribution of different HBV DNA forms in plasma and peripheral blood mononuclear cells (PBMCs) of chronically infected patients with low or undetectable HBV plasma viremia 215
A Comparison of Sanger Sequencing and Amplicon-Based Next Generation Sequencing Approaches for the Detection of HIV-1 Drug Resistance Mutations 214
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 211
Prevalence of HIV-1 Subtypes and Drug Resistance-Associated Mutations in HIV-1-Positive Treatment-Naive Pregnant Women in Pointe Noire, Republic of the Congo (Kento-Mwana Project) 207
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 205
Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy 202
Impact of extensive HIV-1 variability on molecular diagnosis in the Congo Basin 201
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients 193
Unique domain for a unique target: selective inhibitors of host cell DDX3X to fight emerging viruses 192
Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study 192
Impact of remote vs. local sampling on sensitivity of genotypic antiretroviral resistance testing 191
Decreased neutralization of the Eta SARS-CoV-2 variant by sera of previously infected and uninfected vaccinated individuals 190
Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro 183
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry 183
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge 177
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 165
Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects 163
Use of peripheral blood DNA for genotypic antiretroviral resistance testing in drug-naïve HIV-infected subjects. 159
Residual phenotypic susceptibility to doravirine in multidrug resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry 156
PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests” 154
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19 150
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants 148
Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy 147
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 147
Sofosbuvir selects for drug-resistant amino acid variants in the zika virus RNA-dependent RNA-polymerase complex in vitro 144
In vitro anti-sars-cov-2 activity of selected metal compounds and potential molecular basis for their actions based on computational study 144
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 142
Frequent Detection of Antiretroviral Drug Resistance in HIV-1-Infected Orphaned Children Followed at a Donor-Funded Rural Pediatric Clinic in Dodoma, Tanzania 138
Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes 132
Role of phenotypic investigation in the era of routine genotypic HIV-1 drug resistance testing 132
null 129
Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database 123
null 121
null 114
null 114
Recombination analysis and structure prediction show correlation between breakpoint clusters and RNA hairpins in the pol gene of HIV-1 unique recombinant forms 112
Predictors of Virological Failure Among People Living with HIV Switching from an Effective First-Line Antiretroviral Regimen 110
Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network) 98
Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests 97
Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance 95
Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors 94
Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study 83
HIV-1 A1 subtype epidemic in Italy originated from Africa and Eastern Europe and shows a high frequency of transmission chains involving intravenous drug users 82
Marked decrease in acquired resistance to antiretrovirals in latest years in Italy 80
HIV-1 nucleocapsid inhibitors 69
Identification of a possible ancestor of the subtype A1 HIV type 1 variant circulating in the former Soviet Union (Aids Research and Human Retroviruses) 47
Molecular Epidemiology of HIV-1 in Eastern Europe and Russia 45
null 32
Feasibility and reproducibility of HIV-1 genotype resistance test in very-low-level viremia 15
Persistence of CXCR4-tropic virus in people living with four-class drug-resistant HIV and its clinical impact in the modern antiretroviral era 13
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry 13
All-Cause Mortality in People With Four-Class Drug-Resistant HIV: A Matched Cohort Analysis With Data From the PRESTIGIO Registry 10
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry 9
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry 7
Totale 16.140
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.069 0 130 82 117 78 50 63 54 71 109 114 201
2022/20231.326 72 186 143 155 129 236 69 95 96 79 43 23
2023/20241.061 33 24 75 65 15 302 376 31 4 18 25 93
2024/20252.279 50 94 294 115 282 171 78 142 206 114 236 497
2025/20265.845 402 746 757 776 1.259 198 554 187 199 292 127 348
2026/2027387 260 127 0 0 0 0 0 0 0 0 0 0
Totale 16.140